Skip to main content
Press Releases

Cidara Therapeutics Completes Enrollment in Phase 2 RADIANT Trial Evaluating Novel Antifungal CD101 Topical in Vulvovaginal Candidiasis

Topline Data Expected in First Quarter 2017 SAN DIEGO - Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced the completion of patient enrollment in the RADIANT trial, a Phase 2 randomized trial evaluating the safety, tolerability and efficacy of two topical treatment regimens of the novel echinocandin antifungal, CD101, in women with moderate to severe acute vulvovaginal candidiasis (VVC). CD101 topical is the first and only agent in…
wpengine
January 4, 2017
Press Releases

Newly Published Data Reinforce Growing Body of Evidence Supporting Cidara Therapeutics’ Lead Antifungal CD101

Data Showcase Compound's Discovery through Development and Potential to Expand Echinocandin Utility Across Multiple Infectious-Disease Indications SAN DIEGO - Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that data from preclinical and clinical studies evaluating the company's novel echinocandin antifungal CD101 appear in the December 5 online issue of the journal Antimicrobial Agents and Chemotherapy (AAC). These latest findings add to the growing body of published scientific evidence that…
wpengine
December 14, 2016
Press Releases

Cidara Therapeutics’ Presentations at ASH 2016 to Highlight Potential Role of Novel Antifungal CD101 in Patients with Hematologic Malignancies

SAN DIEGO - Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that data from preclinical and clinical studies evaluating its novel echinocandin antifungal CD101 will be presented at the 58th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in San Diego from December 3-6, 2016. CD101 is Cidara's lead antifungal drug candidate and the only long-acting antifungal in the echinocandin class. "Patients with blood cancers…
wpengine
November 28, 2016
Press Releases

Cidara Provides Corporate Update and Reports Third Quarter 2016 Financial Results

SAN DIEGO, Nov. 10, 2016 -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial results for the three months ended September 30, 2016 and provided an update on its corporate activities and product pipeline. "Cidara made major progress in the third quarter and achieved significant clinical and corporate milestones. We enrolled the first patient in our Phase 2 STRIVE study of CD101 IV in candidemia, announced CD201 as…
wpengine
November 10, 2016
Press Releases

Cidara Therapeutics to Present Data on Novel Antifungal CD101 at the Global Joint Conference of ICHS and INFOCUS

Data Will Highlight the Potential Broad Clinical Utility and Subcutaneous Administration of CD101 for Invasive Fungal Infections SAN DIEGO - Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that data from preclinical and clinical studies evaluating its novel echinocandin antifungal CD101 as a potential treatment for invasive fungal infections will be presented at the joint conference of the International Immunocompromised Host Society (ICHS) and INFOCUS Latinomérica from November…
wpengine
November 10, 2016
Press Releases

Cidara Therapeutics to Present at the Stifel 2016 Healthcare Conference

SAN DIEGO, Nov. 08, 2016 -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced it will participate in the Stifel 2016 Healthcare Conference on Tuesday, November 15, 2016. Jeffrey Stein, Ph.D., president and chief executive officer of Cidara, is scheduled to present at 8:00 a.m. EST (5:00 a.m. PST). The conference is being held in New York City. A live audio webcast and replay will be available in the…
wpengine
November 8, 2016
Press Releases

Cidara Therapeutics and Square 1 Bank Announce $20 Million Credit Facility

SAN DIEGO, Nov. 02, 2016 -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, and Square 1 Bank, a division of Pacific Western Bank, announced they have entered into an agreement for a $20 million credit facility. Proceeds from the facility will provide working capital to support Cidara's CD101 and CD201 programs which are in development to treat serious fungal and multi-drug resistant bacterial infections.…
wpengine
November 2, 2016
Press Releases

Cidara Therapeutics Announces Data from Studies of Novel Antifungal CD101 to be Presented at ACCP and IDWeek Annual Meetings

Data Highlight Safety and Efficacy of CD101 IV and CD101 Topical for the Treatment of Fungal Infections SAN DIEGO - Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that data from preclinical and clinical studies evaluating its novel echinocandin antifungal CD101 as a potential treatment for serious infections will be presented at the 2016 American College of Clinical Pharmacy (ACCP) Annual Meeting in Hollywood, Florida from October 23-26…
wpengine
October 24, 2016
Press Releases

Cidara Therapeutics Announces Closing of Public Offering of Common Stock, Including Exercise of Underwriter’s Option to Purchase Additional Shares

SAN DIEGO, Oct. 13, 2016 -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced the closing of its previously announced underwritten public offering of 2,475,248 shares of its common stock, plus 277,389 additional shares sold pursuant to the underwriter's partial exercise of its option to purchase additional shares, each at a price to the public of $10.10 per share. Including this option exercise, the gross proceeds to Cidara from…
wpengine
October 13, 2016
Press Releases

Cidara Therapeutics Announces Pricing of Public Offering of Common Stock

SAN DIEGO, Oct. 07, 2016 -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced the pricing of an underwritten public offering of 2,475,248 shares of its common stock at a price to the public of $10.10 per share. The gross proceeds to Cidara from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $25.0 million. The offering is expected to close…
wpengine
October 7, 2016